Trial Profile

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS-986315 (Primary) ; Cetuximab (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

23 Oct 2024 Status changed from active, no longer recruiting to discontinued.
27 Jun 2024 Planned primary completion date changed from 1 Apr 2024 to 22 Aug 2024.
09 Feb 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com